- Home
- DX vs AUPH Comparison
DX vs AUPH Comparison
Compare DX & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DX
- AUPH
- Stock Information
- Founded
- DX 1987
- AUPH 1993
- Country
- DX United States
- AUPH Canada
- Employees
- DX N/A
- AUPH N/A
- Industry
- DX Real Estate Investment Trusts
- AUPH Biotechnology: Pharmaceutical Preparations
- Sector
- DX Real Estate
- AUPH Health Care
- Exchange
- DX Nasdaq
- AUPH Nasdaq
- Market Cap
- DX 1.3B
- AUPH 1.1B
- IPO Year
- DX N/A
- AUPH 1999
- Fundamental
- Price
- DX $12.16
- AUPH $8.77
- Analyst Decision
- DX Buy
- AUPH Strong Buy
- Analyst Count
- DX 4
- AUPH 2
- Target Price
- DX $12.50
- AUPH $11.50
- AVG Volume (30 Days)
- DX 3.8M
- AUPH 1.4M
- Earning Date
- DX 07-21-2025
- AUPH 07-31-2025
- Dividend Yield
- DX 16.71%
- AUPH N/A
- EPS Growth
- DX N/A
- AUPH N/A
- EPS
- DX 0.79
- AUPH 0.27
- Revenue
- DX $108,019,000.00
- AUPH $247,295,000.00
- Revenue This Year
- DX N/A
- AUPH $12.15
- Revenue Next Year
- DX $23.37
- AUPH $18.31
- P/E Ratio
- DX $15.41
- AUPH $31.76
- Revenue Growth
- DX N/A
- AUPH 29.20
- 52 Week Low
- DX $10.79
- AUPH $5.20
- 52 Week High
- DX $14.52
- AUPH $10.67
- Technical
- Relative Strength Index (RSI)
- DX 47.19
- AUPH 66.00
- Support Level
- DX $12.00
- AUPH $7.71
- Resistance Level
- DX $12.14
- AUPH $8.29
- Average True Range (ATR)
- DX 0.17
- AUPH 0.25
- MACD
- DX -0.00
- AUPH 0.03
- Stochastic Oscillator
- DX 48.57
- AUPH 84.40
About DX Dynex Capital Inc.
Dynex Capital Inc is an internally managed mortgage real estate investment trust, which invests in mortgage-backed securities. The company invests in residential and commercial mortgage-backed securities. Its objective is to provide attractive risk-adjusted returns to shareholders over the long term that are reflective of a leveraged, high quality fixed income portfolio with a focus on capital preservation. Its investments consist principally of Agency mortgage-backed securities including, residential MBS and commercial MBS.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.